These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 32268374)

  • 21. Letter to the editor: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in developing a COVID-19 comorbidity-based host risk score.
    Vavougios GD
    Crit Care; 2020 May; 24(1):242. PubMed ID: 32430049
    [No Abstract]   [Full Text] [Related]  

  • 22. COVID-19 and ACEI/ARB: Not Associated?
    Hajra A; Bandyopadhyay D
    Am J Hypertens; 2020 Aug; 33(8):788. PubMed ID: 32415832
    [No Abstract]   [Full Text] [Related]  

  • 23. Comment on "ACE inhibitors and COVID-19: We don't know yet".
    Ilcol TB; Cure E; Cumhur Cure M
    J Card Surg; 2020 Jun; 35(6):1387. PubMed ID: 32531125
    [No Abstract]   [Full Text] [Related]  

  • 24. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
    Vázquez-Cornejo E
    Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
    Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
    Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
    [No Abstract]   [Full Text] [Related]  

  • 26. COVID-19: The heart of the issue.
    Woodward B; Kermali M
    J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802
    [No Abstract]   [Full Text] [Related]  

  • 27. EMA advice on renin-angiotensin system medicines during covid-19 pandemic.
    Drug Ther Bull; 2020 Jun; 58(6):85. PubMed ID: 32295811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.
    Dworakowska D; Grossman AB
    J Physiol Pharmacol; 2020 Apr; 71(2):. PubMed ID: 32633235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Letter to the editors in response to: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic (Cure et al.).
    Ekiz T; Kara M; Özçakar L
    Diabetes Metab Syndr; 2020; 14(4):525-526. PubMed ID: 32402930
    [No Abstract]   [Full Text] [Related]  

  • 30. Heartbeat: interaction of renin-angiotensin-aldosterone blocking drugs with COVID-19 disease susceptibility and severity.
    Otto CM
    Heart; 2020 Oct; 106(19):1451-1453. PubMed ID: 32928982
    [No Abstract]   [Full Text] [Related]  

  • 31. The COVID-19 Pandemic and Mayo Clinic Proceedings.
    Nath KA
    Mayo Clin Proc; 2020 May; 95(5):835-836. PubMed ID: 32370843
    [No Abstract]   [Full Text] [Related]  

  • 32. Cardiovascular disease and the impact of COVID-19.
    Yoganathan A; Sajjad MS; Harky A
    J Card Surg; 2020 Aug; 35(8):2113. PubMed ID: 32542799
    [No Abstract]   [Full Text] [Related]  

  • 33. Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial.
    Thomas LE; Li F; Pencina MJ
    JAMA; 2020 Jun; 323(23):2417-2418. PubMed ID: 32369102
    [No Abstract]   [Full Text] [Related]  

  • 34. Controversial Relationship Between Renin-Angiotensin System Inhibitors and Severity of COVID-19: Announcing a Large Multicentre Case-Control Study in Italy.
    Di Castelnuovo A; De Caterina R; de Gaetano G; Iacoviello L
    Hypertension; 2020 Aug; 76(2):312-313. PubMed ID: 32383624
    [No Abstract]   [Full Text] [Related]  

  • 35. The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.
    Tsioufis C; Dimitriadis K; Tousoulis D
    Hellenic J Cardiol; 2020; 61(1):31-33. PubMed ID: 32450334
    [No Abstract]   [Full Text] [Related]  

  • 36. In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension.
    Yuan Y; Liu D; Zeng S; Wang S; Xu S; Wang Y; Yu R; Gao Y; Li H; Feng X; Zhou N; Zhao C; Gao Q
    J Infect; 2020 Nov; 81(5):816-846. PubMed ID: 32800800
    [No Abstract]   [Full Text] [Related]  

  • 37. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.
    Guo X; Zhu Y; Hong Y
    Hypertension; 2020 Aug; 76(2):e13-e14. PubMed ID: 32458694
    [No Abstract]   [Full Text] [Related]  

  • 38. The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 1.
    Frishman WH
    Cardiol Rev; 2020; 28(4):161-162. PubMed ID: 32427638
    [No Abstract]   [Full Text] [Related]  

  • 39. ACEing COVID-19: A Role for Angiotensin Axis Inhibition in SARS-CoV-2 Infection?
    Murthy VL; Koupenova M; Shah RV
    Circ Res; 2020 Jun; 126(12):1682-1684. PubMed ID: 32302248
    [No Abstract]   [Full Text] [Related]  

  • 40. Chronic Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Is High Among Intensive Care Unit Patients With Non-COVID-19 Sepsis but Carries a Moderately Increased Risk of Death.
    Sunden-Cullberg J
    Hypertension; 2020 Jun; 75(6):e15-e16. PubMed ID: 32275190
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.